Figure 3.
Cumulative incidence rate of LRR as first failure within Luminal A, TNBC, and HER2‐positive with and without target treatment. TNBC, Triple‐negative breast cancer
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.